Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANCN Anchiano Therapeutics	$1.22 +1.4%	$21.77	$0.51 ▼ $10.55	$9.05M	0.93	3.15 million shs	38,266 shs
CLNN Clene	$4.13 +1.1%	$3.08	$2.28 ▼ $8.60	$37.06M	0.49	88,351 shs	69,970 shs
QNTM Quantum Biopharma	$19.69 +3.6%	$9.77	$2.70 ▼ $21.43	$53.28M	0.54	953,155 shs	445,730 shs
RVPH Reviva Pharmaceuticals	$0.73 -6.9%	$0.83	$0.49 ▼ $4.28	$33.95M	0.11	1.11 million shs	771,222 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANCN Anchiano Therapeutics	-7.48%	-10.63%	-3.01%	-13.47%	+20.28%
CLNN Clene	-2.86%	-5.77%	+54.55%	-7.90%	-50.72%
QNTM Quantum Biopharma	+23.62%	+38.18%	+125.65%	+288.55%	+1,899,999,900.00%
RVPH Reviva Pharmaceuticals	-1.63%	-2.50%	-6.51%	-29.73%	-48.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLNN Clene	2.5726 of 5 stars	3.6	3.0	0.0	0.0	1.1	2.5	0.6
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	2.7602 of 5 stars	3.6	1.0	0.0	0.0	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANCN Anchiano Therapeutics	0.00	N/A	N/A	N/A
CLNN Clene	3.17	Buy	$40.00	869.46% Upside
QNTM Quantum Biopharma	0.00	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	3.29	Buy	$9.00	1,139.16% Upside

Current Analyst Ratings Breakdown

Latest ANCN, QNTM, RVPH, and CLNN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/24/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
4/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/8/2025	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/1/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.00
3/24/2025	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/24/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	$2.01 per share	N/A
CLNN Clene	$350K	105.90	N/A	N/A	$2.09 per share	1.97
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$21.29 per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANCN Anchiano Therapeutics	-$27.12M	-$3.46	8.13	N/A	N/A	N/A	36.08%	27.40%	N/A
CLNN Clene	-$49.50M	-$4.04	N/A	N/A	N/A	-8,556.77%	-1,106.30%	-85.11%	8/6/2025 (Estimated)
QNTM Quantum Biopharma	-$17.90M	-$15.98	N/A	N/A	N/A	N/A	-84.21%	-62.63%	8/13/2025 (Estimated)
RVPH Reviva Pharmaceuticals	-$39.26M	-$0.79	N/A	N/A	N/A	N/A	N/A	-252.53%	8/13/2025 (Estimated)

Latest ANCN, QNTM, RVPH, and CLNN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	RVPH Reviva Pharmaceuticals	-$0.21	-$0.13	+$0.08	-$0.13	N/A	N/A
5/14/2025	Q1 2025	QNTM Quantum Biopharma	-$0.37	-$1.41	-$1.04	-$3.53	$2.09 million	$2.09 million
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million
3/31/2025	Q4 2024	RVPH Reviva Pharmaceuticals	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
3/28/2025	Q4 2024	QNTM Quantum Biopharma	-$0.80	-$2.89	-$2.09	-$2.89	$0.92 million	N/A
3/24/2025	Q4 2024	CLNN Clene	-$1.21	-$1.67	-$0.46	-$1.67	$0.13 million	$0.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANCN Anchiano Therapeutics	N/A	3.25	3.25
CLNN Clene	N/A	0.83	0.82
QNTM Quantum Biopharma	N/A	3.76	3.76
RVPH Reviva Pharmaceuticals	N/A	0.39	0.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANCN Anchiano Therapeutics	9.05%
CLNN Clene	23.28%
QNTM Quantum Biopharma	1.24%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
ANCN Anchiano Therapeutics	6.88%
CLNN Clene	35.30%
QNTM Quantum Biopharma	8.53%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANCN Anchiano Therapeutics	16	7.42 million	N/A	Not Optionable
CLNN Clene	100	8.98 million	6.24 million	Optionable
QNTM Quantum Biopharma	N/A	2.71 million	1.76 million	N/A
RVPH Reviva Pharmaceuticals	5	46.74 million	24.35 million	Optionable

ANCN, QNTM, RVPH, and CLNN Headlines

Recent News About These Companies

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $9.00 Average Price Target from Brokerages

June 13 at 1:15 AM | americanbankingnews.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Pharmaceuticals' (RVPH) Buy Rating Reaffirmed at D. Boral Capital

June 5, 2025 | americanbankingnews.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.com

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)

May 4, 2025 | theglobeandmail.com

Reviva to Participate in the Citizens Life Sciences Conference

April 29, 2025 | finance.yahoo.com

RVPH: M&A Deals Highlight Brilaroxazine Value

April 7, 2025 | finance.yahoo.com

Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)

April 5, 2025 | markets.businessinsider.com

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

March 31, 2025 | markets.businessinsider.com

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

March 30, 2025 | globenewswire.com

Why Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%

March 7, 2025 | aaii.com

Unusually active option classes on open February 12th

February 12, 2025 | markets.businessinsider.com

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | globenewswire.com

Reviva to Participate in the 2025 BIO CEO & Investor Conference

January 30, 2025 | globenewswire.com

Reviva Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright

January 22, 2025 | markets.businessinsider.com

Reviva Pharmaceuticals Holdings Inc (RVPH) Stock Sees Market Value Hit $93.16 million: What Are the Implications?

January 22, 2025 | bovnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANCN, QNTM, RVPH, and CLNN Company Descriptions

Anchiano Therapeutics NASDAQ:ANCN

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Clene NASDAQ:CLNN

$4.13 +0.05 (+1.13%)

Closing price 03:59 PM Eastern

Extended Trading

$4.10 -0.03 (-0.63%)

As of 04:22 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Quantum Biopharma NASDAQ:QNTM

$19.69 +0.69 (+3.63%)

Closing price 04:00 PM Eastern

Extended Trading

$20.75 +1.06 (+5.38%)

As of 04:38 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.73 -0.05 (-6.88%)

Closing price 04:00 PM Eastern

Extended Trading

$0.75 +0.02 (+3.40%)

As of 04:26 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time